Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Scientific advisers
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
    • Patients
    • Expanded access policy
  • Research & Development
    • Projects
      • KL1333
      • NV354
      • Early programs
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • Capital Markets Day 2020
      • Mitochondria Day 2020
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Other financial information

Tilläggsprospekt/Supplementary prospectus 2020Download
Prospekt/Prospectus 2020Download
Prospekt/Prospectus 2019Download
Tilläggsprospekt/Supplementary prospectus 2018Download
Prospekt/Prospectus 2018Download
Prospekt/Prospectus 2016Download
Prospekt/Prospectus 2015Download
Prospekt (svenskt) 2014Download
Prospectus (English) 2014Download
Prospekt/Prospectus 2013Download
Prospekt/Prospectus 2012Download
Prospekt/Prospectus 2010Download
Prospekt/Prospectus 2008Download
Investor relations

Annual reports

Here you'll find all Abliva's annual reports.

Investor relations

Interim reports

Here you'll find all Abliva's interim reports.

STEP 1

The information and documents on this part of Abliva AB’s (publ) (“Abliva“) website may not, according to law and regulations, be made available to certain persons, and consequently, persons whom wish to access the information and documents must inform themselves of and act in accordance with such restrictions. We ask you to read the text below and submit the following confirmation every time you want to enter this website. Your confirmation must be true.

This material is not intended for and must not be accessed by persons resident or located in the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other country where participation in Abliva’s rights issue or purchase or sale of subscription rights, paid subscribed shares or newly issued shares is not permitted.

Offers to subscribe for shares in Abliva according to prospectus is not, directly or indirectly, being made to such persons whose participation require additional prospectuses, registration or other measures in addition to the requirements under Swedish law. Prospectus and other related documents may not be distributed in or to any country where the distribution or the offer require additional registration or other measures in addition to the requirements under Swedish law or constitute a violation of applicable laws or regulations in such country.

Next

You are not authorized to view the content on this page.

Back to start page

STEP 2

Subscription rights, paid subscribed shares (“BTA”) or newly issued shares have not been registered and will not be registered under the United States Securities Act of 1933, as amended, nor under any corresponding law in any state of the United States. Offers do not include persons resident in mentioned countries or in any other country where the offer or distribution of the prospectus constitute a violation of applicable laws or regulations, or require additional prospectuses, registrations or other measures in addition to the requirements under Swedish law. A notification of subscription of shares in violation of the above may be considered invalid. Accordingly, subscription rights, BTAs or shares may not be, directly or indirectly, offered, resold or delivered in or to countries where action as above is required or to shareholders domiciled as above.

By accepting below, I confirm that I have read and accepted to be bound by the information, instructions, terms and conditions provided on this part of the website and confirm that I am not located in the United States of America, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other country where the offer or distribution of the prospectus or other related documents constitute a violation of applicable laws or regulations or require additional prospectuses, registrations or other measures in addition to the requirements under Swedish law.

ConfirmDecline

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage
  2. Investors
  3. Other financial information

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • BD Contact
  • Partnering

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
Scheelevägen 2
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookies policy | Privacy policy | Terms and Conditions

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all